CN102361869A - 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 - Google Patents

在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 Download PDF

Info

Publication number
CN102361869A
CN102361869A CN2010800132941A CN201080013294A CN102361869A CN 102361869 A CN102361869 A CN 102361869A CN 2010800132941 A CN2010800132941 A CN 2010800132941A CN 201080013294 A CN201080013294 A CN 201080013294A CN 102361869 A CN102361869 A CN 102361869A
Authority
CN
China
Prior art keywords
base
compound
isoxazole
carboxylic acid
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800132941A
Other languages
English (en)
Chinese (zh)
Inventor
W.J.皮茨
A.J.戴克曼
S.H.斯珀格尔
S.H.沃特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102361869A publication Critical patent/CN102361869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800132941A 2009-01-23 2010-01-22 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 Pending CN102361869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14683709P 2009-01-23 2009-01-23
US61/146,837 2009-01-23
PCT/US2010/021694 WO2010085582A1 (en) 2009-01-23 2010-01-22 Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
CN102361869A true CN102361869A (zh) 2012-02-22

Family

ID=41809079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800132941A Pending CN102361869A (zh) 2009-01-23 2010-01-22 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物

Country Status (5)

Country Link
US (1) US8404672B2 (enExample)
EP (1) EP2389377B1 (enExample)
JP (1) JP2012515788A (enExample)
CN (1) CN102361869A (enExample)
WO (1) WO2010085582A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864754A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
CN105026362A (zh) * 2013-02-21 2015-11-04 百时美施贵宝公司 双环化合物
CN107827837A (zh) * 2017-11-21 2018-03-23 苏州朗科生物技术股份有限公司 鞘氨醇‑1‑磷酸受体调节剂化合物及其制备方法与应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9222728B2 (en) 2006-04-24 2015-12-29 Medinstill Development Llc Penetrable and resealable lyophilization device
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
NZ540321A (en) 2002-11-15 2007-09-28 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
CA2509218C (en) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
MX2007011670A (es) 2005-03-23 2007-11-15 Actelion Pharmaceuticals Ltd Derivados de benzo(c) tiofeno hidrogenados como inmunomoduladores.
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
WO2006131336A1 (en) 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
KR101470659B1 (ko) 2006-09-07 2014-12-08 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-4-일 유도체
RU2442780C2 (ru) 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
JP2010513283A (ja) 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
CL2007003784A1 (es) 2006-12-21 2008-06-27 Abbott Lab Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
JP5191497B2 (ja) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド Ｓ１ｐ受容体調節化合物およびその使用
US8796253B2 (en) 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
JP5727223B2 (ja) 2007-10-04 2015-06-03 メルク セローノ ソシエテ アノニム オキサジアゾール・ジアリール化合物
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
KR20100092473A (ko) 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
PL2913326T3 (pl) 2008-05-14 2020-11-16 The Scripps Research Institute Nowe modulatory receptorów fosforanu sfingozyny
EP2350006A1 (en) 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8314130B2 (en) 2008-10-01 2012-11-20 Synta Pharmaceuticals Corp. Compounds inclunding substituted pyridines for inflammation and immune-related uses
WO2010065760A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864754A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
CN103864754B (zh) * 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
CN105026362A (zh) * 2013-02-21 2015-11-04 百时美施贵宝公司 双环化合物
CN105026362B (zh) * 2013-02-21 2017-07-14 百时美施贵宝公司 双环化合物
CN107827837A (zh) * 2017-11-21 2018-03-23 苏州朗科生物技术股份有限公司 鞘氨醇‑1‑磷酸受体调节剂化合物及其制备方法与应用
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用

Also Published As

Publication number Publication date
WO2010085582A1 (en) 2010-07-29
US8404672B2 (en) 2013-03-26
EP2389377B1 (en) 2014-07-16
EP2389377A1 (en) 2011-11-30
US20120022041A1 (en) 2012-01-26
JP2012515788A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
CN102361869A (zh) 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
EP2382211B1 (en) Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2680844B1 (en) Amino-quinolines as kinase inhibitors
CN110678459B (zh) 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
AU2020378407B2 (en) Heterocyclic RIP1 inhibitory compounds
JP5728487B2 (ja) 三環式ヘテロ環化合物
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
CN103124727A (zh) 取代的3-苯基-1,2,4-噁二唑化合物
EP2603218A1 (en) Quinolyl amines as kinase inhibitors
CN102548989A (zh) 1-磷酸-鞘氨醇受体激动剂
CN103237795A (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
WO2011133734A1 (en) 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
EP4188928A1 (en) Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
CA2934456C (en) Fused heterocyclic compounds as ion channel modulators
HK40020738B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120222

C20 Patent right or utility model deemed to be abandoned or is abandoned